EMA panel recommends 2 blood cancer drugs for conditional approval


The European Medicines Agency has recommended idecabtagene vicleucel, or Abecma, and tafasitamab, or Minjuvi, for conditional marketing authorization in Europe. The two blood cancer drugs have already been approved in the US.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.